Search Result

No matches for "

51019

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

By Targets:	5-HT Receptor (5) Akt (1) Amyloid-β (1) Angiotensin Receptor (3) Apoptosis (2) Autophagy (1) c-Met/HGFR (2) Checkpoint Kinase (Chk) (1) Isotope-Labeled Compounds (3) MicroRNA (8) Microtubule/Tubulin (1) Necroptosis (1) Opioid Receptor (2) Polo-like Kinase (PLK) (1) Potassium Channel (4) Prostaglandin Receptor (2) Reference Standards (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (3) Metabolic Disease (2) Neurological Disease (10)
Oligonucleotides:	miRNA mimics (2) miRNA antagomirs (2) miRNA agomirs (2) MicroRNAs (8) miRNA inhibitors (2)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14149

Cisapride 2 Publications Verification R 51619; (±)-Cisaprid	5-HT Receptor Potassium Channel	Neurological Disease
Cisapride (R 51619) is an orally active 5-HT₄ receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-125203

PV-1019 2 Publications Verification NSC 744039	Checkpoint Kinase (Chk)	Cancer
PV-1019 (NSC 744039) is a potent, selective Chk2 inhibitor with an IC₅₀ value of 24 nM. PV-1019 inhibits the Topotecan (HY-13768)-induced Chk2 autophosphorylation. PV-1019 inhibits IR-induced apoptosis .

HY-104006

CYM51010	Opioid Receptor	Neurological Disease
CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC₅₀ of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .

HY-108563

SC 51089	Prostaglandin Receptor	Neurological Disease
SC 51089 is a selective antagonist of prostaglandin E₂ EP1 receptor, with K_is of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 exhibits neuroprotective activity .

HY-108563A

*SC 51089* free base** 1 Publications Verification	Prostaglandin Receptor	Neurological Disease
SC 51089 free base is a selective antagonist of prostaglandin E₂ EP1 receptor, with K_is of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 free base exhibits neuroprotective activity .

HY-152849

Boditrectinib HL5101	c-Met/HGFR	Cancer
Boditrectinib is a potent tyrosine kinase inhibitor. Boditrectinib serves as an antineoplastic agent. Boditrectinib is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases .

HY-19118

KP1019 FFC14A	Apoptosis	Cancer
KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells .

HY-145552

Azilsartan mepixetil QR-01019	Angiotensin Receptor	Cardiovascular Disease
Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-RI03263A

*mmu-miR-5119* antagomir**	MicroRNA	Cancer
mmu-miR-5119 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-5119 antagomir mmu-miR-5119 antagomir

HY-152849A

Boditrectinib oxalate HL5101 oxalate	c-Met/HGFR	Cancer
Boditrectinib oxalate is a potent tyrosine kinase inhibitor. Boditrectinib oxalate serves as an antineoplastic agent. Boditrectinib oxalate is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases .

HY-14149A

Cisapride monohydrate 2 Publications Verification R 51619 monohydrate; (±)-Cisaprid monohydrate	5-HT Receptor	Neurological Disease Metabolic Disease
Cisapride monohydrate is an orally and potent 5-HT₄ receptor agonist and hERG inhibitor. Cisapride monohydrate is an prokinetic agent which facilitates or restores motility throughout the length of the gastrointestinal tract. Cisapride monohydrate stimulates gastrointestinal motor activity through an indirect mechanism involving the release of acetylcholine mediated by postganglionic nerve endings in the myenteric plexus of the gut .

HY-14149R

Cisapride (Standard) R 51619 (Standard); (±)-Cisaprid (Standard)	Reference Standards 5-HT Receptor Potassium Channel	Neurological Disease
Cisapride (Standard) is the analytical standard of Cisapride. This product is intended for research and analytical applications. Cisapride (R 51619) is an orally active 5-HT₄ receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-16371

Ortataxel IDN 5109; BAY 59-8862	Microtubule/Tubulin	Cancer
Ortataxel (IDN 5109; BAY 59-8862) is a derivative of Paclitaxel (HY-B0015). Ortataxel exhibits activity against multiple drug-sensitive and resistant cancer cell lines .

HY-123485

PPI-1019	Amyloid-β	Neurological Disease
PPI-1019 is an amyloid beta (Aβ) inhibitor. PPI-1019 can be used in the research of neurological diseases and Alzheimer's disease .

HY-145552A

Azilsartan mepixetil potassium QR-01019K	Angiotensin Receptor	Cardiovascular Disease Metabolic Disease
Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensin II receptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-RI03263

*mmu-miR-5119* inhibitor**	MicroRNA	Cancer
mmu-miR-5119 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-5119 inhibitor mmu-miR-5119 inhibitor

HY-R03247

*mmu-miR-5101* mimic**	MicroRNA	Cancer
mmu-miR-5101 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-5101 mimic mmu-miR-5101 mimic

HY-145552S

Azilsartan mepixetil-d5 QR-01019-d-d₅	Isotope-Labeled Compounds Angiotensin Receptor	Cardiovascular Disease
Azilsartan mepixetil-d₅ (QR-01019-d₅) is deuterium labeled Azilsartan mepixetil. Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-14149S

Cisapride-d6 R51619-d₆; (±)-Cisaprid-d₆	Isotope-Labeled Compounds 5-HT Receptor Potassium Channel	Neurological Disease
Cisapride-d₆ (R51619-d₆) is deuterium labeled Cisapride. Cisapride (R 51619) is an orally active 5-HT₄ receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-W777120

Cisapride-13C,d3 R 51619-13C,d3; (±)-Cisaprid-_{13_{C_,d₃}}	Isotope-Labeled Compounds 5-HT Receptor Potassium Channel	Neurological Disease
Cisapride- ¹³C,d₃ (R 51619- ¹³C,d₃) is the deuteriumand ¹³C-labeled Cisapride (HY-14149). Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-104006R

CYM51010 (Standard)	Reference Standards Opioid Receptor	Neurological Disease
CYM51010 (Standard) is the analytical standard of CYM51010 (HY-104006). This product is intended for research and analytical applications. CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC₅₀ of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .

HY-W162436

MCC1019	Polo-like Kinase (PLK) Akt Apoptosis Necroptosis Autophagy	Cancer
MCC1019 is a selective PLK1 PBD inhibitor with an IC₅₀ of 16.4 μmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer .

HY-R03247A

*mmu-miR-5101* agomir**	MicroRNA	Cancer
mmu-miR-5101 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-5101 agomir mmu-miR-5101 agomir

HY-R03263A

*mmu-miR-5119* agomir**	MicroRNA	Cancer
mmu-miR-5119 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-5119 agomir mmu-miR-5119 agomir

HY-RI03247

*mmu-miR-5101* inhibitor**	MicroRNA	Cancer
mmu-miR-5101 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-5101 inhibitor mmu-miR-5101 inhibitor

HY-R03263

*mmu-miR-5119* mimic**	MicroRNA	Cancer
mmu-miR-5119 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-5119 mimic mmu-miR-5119 mimic

HY-RI03247A

*mmu-miR-5101* antagomir**	MicroRNA	Cancer
mmu-miR-5101 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-5101 antagomir mmu-miR-5101 antagomir

Cat. No.	Product Name	Target	Research Area

HY-123485

PPI-1019	Amyloid-β	Neurological Disease
PPI-1019 is an amyloid beta (Aβ) inhibitor. PPI-1019 can be used in the research of neurological diseases and Alzheimer's disease .

Cat. No.	Product Name	Chemical Structure

HY-145552S

Azilsartan mepixetil-d5
Azilsartan mepixetil-d₅ (QR-01019-d₅) is deuterium labeled Azilsartan mepixetil. Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

Azilsartan mepixetil-d5

Azilsartan mepixetil-d₅ (QR-01019-d₅) is deuterium labeled Azilsartan mepixetil. Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-14149S

Cisapride-d6
Cisapride-d₆ (R51619-d₆) is deuterium labeled Cisapride. Cisapride (R 51619) is an orally active 5-HT₄ receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-W777120

Cisapride-13C,d3
Cisapride- ¹³C,d₃ (R 51619- ¹³C,d₃) is the deuteriumand ¹³C-labeled Cisapride (HY-14149). Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

Host:	Mouse (3) Rabbit (2)
Reactivity:	Human (5) Bovine (1) Mouse (3) Pig (1)
Application:	IHC-P (1) ICC/IF (2) WB (5) FC (1) ELISA (1)
Isotype:	IgG (3)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (4) Recombinant (1)
Modification:	Phosphorylated (1) Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85427

	Dynactin 1 Antibody (YA5119) DCTN1; Dynactin subunit 1; 150 kDa dynein-associated polypeptide; DAP-150; DP-150; p135; p150-glued	WB, ICC/IF	Human, Mouse, Bovine, Pig
	Dynactin 1 Antibody (YA5119) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Dynactin 1.

HY-P81296A

	Phospho-delta 1 Catenin (Ser268) Antibody (YA1019) CAS; p120; BCDS2; CTNND; P120CAS; P120CTN; p120(CAS); p120(CTN)	WB	Human, Mouse
	Phospho-delta 1 Catenin (Ser268) Antibody (YA1019) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-delta 1 Catenin (Ser268).

HY-P81296AA

	Phospho-delta 1 Catenin (Ser268) Antibody (YA1019)(PBS only) CAS; p120; BCDS2; CTNND; P120CAS; P120CTN; p120(CAS); p120(CTN)	WB	Human, Mouse
	Phospho-delta 1 Catenin (Ser268) Antibody (YA1019) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-delta 1 Catenin (Ser268).

HY-P85417

	ALDH3A2 Antibody (YA5109) ALDH3A2; ALDH10; FALDH; Fatty aldehyde dehydrogenase; Aldehyde dehydrogenase 10; Aldehyde dehydrogenase family 3 member A2; Microsomal aldehyde dehydrogenase	WB, IHC-P	Human
	ALDH3A2 Antibody (YA5109) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ALDH3A2.

HY-P85327

	Pinch-1 Antibody (YA5019) LIMS1; PINCH; PINCH1; LIM and senescent cell antigen-like-containing domain protein 1; Particularly interesting new Cys-His protein 1; PINCH-1; Renal carcinoma antigen NY-REN-48	WB, ICC/IF, FC, ELISA	Human
	Pinch-1 Antibody (YA5019) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Pinch-1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RI03263A

*mmu-miR-5119* antagomir**		MicroRNAs miRNA antagomirs
mmu-miR-5119 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-RI03263

*mmu-miR-5119* inhibitor**		MicroRNAs miRNA inhibitors
mmu-miR-5119 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

HY-R03247

*mmu-miR-5101* mimic**		MicroRNAs miRNA mimics
mmu-miR-5101 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R03247A

*mmu-miR-5101* agomir**		MicroRNAs miRNA agomirs
mmu-miR-5101 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-R03263A

*mmu-miR-5119* agomir**		MicroRNAs miRNA agomirs
mmu-miR-5119 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-RI03247

*mmu-miR-5101* inhibitor**		MicroRNAs miRNA inhibitors
mmu-miR-5101 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

HY-R03263

*mmu-miR-5119* mimic**		MicroRNAs miRNA mimics
mmu-miR-5119 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-RI03247A

*mmu-miR-5101* antagomir**		MicroRNAs miRNA antagomirs
mmu-miR-5101 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation:		* Country or Region:
* Applicant Name:		* Organization Name:
* Department:
* Email Address:		* Product Name:
Cat. No.:		* Requested quantity:
* Phone Number:
MCE Japan Authorized Agent:	ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: